ALEC Alector Inc

Price (delayed)

$26.73

Market cap

$2.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.69

Enterprise value

$2.08B

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system ...

Highlights
The revenue has increased by 19% since the previous quarter and by 13% year-on-year
ALEC's gross profit is up by 19% from the previous quarter and by 13% YoY
The equity has decreased by 48% YoY and by 19% QoQ
The quick ratio has contracted by 44% YoY and by 24% from the previous quarter

Key stats

What are the main financial stats of ALEC
Market
Shares outstanding
80.88M
Market cap
$2.16B
Enterprise value
$2.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.56
Price to sales (P/S)
99.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.23
Earnings
Revenue
$21.44M
EBIT
-$212.2M
EBITDA
-$204.38M
Free cash flow
-$188.66M
Per share
EPS
-$2.69
Free cash flow per share
-$2.36
Book value per share
$2.31
Revenue per share
$0.27
TBVPS
$4.98
Balance sheet
Total assets
$397.11M
Total liabilities
$212.6M
Debt
$49.6M
Equity
$184.52M
Working capital
$254.94M
Liquidity
Debt to equity
0.27
Current ratio
4.43
Quick ratio
4.32
Net debt/EBITDA
0.38
Margins
EBITDA margin
-953.5%
Gross margin
100%
Net margin
-990%
Operating margin
-1,000.5%
Efficiency
Return on assets
-45.7%
Return on equity
-85.7%
Return on invested capital
-60.6%
Return on capital employed
-65.8%
Return on sales
-990%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALEC stock price

How has the Alector stock price performed over time
Intraday
4.99%
1 week
17.44%
1 month
-1.47%
1 year
89.57%
YTD
76.67%
QTD
28.32%

Financial performance

How have Alector's revenue and profit performed over time
Revenue
$21.44M
Gross profit
$21.44M
Operating income
-$214.47M
Net income
-$212.2M
Gross margin
100%
Net margin
-990%
Alector's net income has decreased by 44% YoY and by 4.9% QoQ
ALEC's operating income is down by 38% year-on-year and by 4.2% since the previous quarter
The net margin has contracted by 28% YoY but it has grown by 12% from the previous quarter
ALEC's operating margin is down by 23% year-on-year but it is up by 12% since the previous quarter

Growth

What is Alector's growth rate over time

Valuation

What is Alector stock price valuation
P/E
N/A
P/B
11.56
P/S
99.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.23
ALEC's EPS is down by 32% YoY and by 4.3% from the previous quarter
ALEC's P/B is 90% above its last 4 quarters average of 5.8
The equity has decreased by 48% YoY and by 19% QoQ
The stock's price to sales (P/S) is 46% more than its last 4 quarters average of 64.8
The revenue has increased by 19% since the previous quarter and by 13% year-on-year

Efficiency

How efficient is Alector business performance
The return on equity has dropped by 68% year-on-year and by 23% since the previous quarter
The return on invested capital has dropped by 60% year-on-year and by 21% since the previous quarter
Alector's ROA has plunged by 60% YoY and by 15% from the previous quarter
ALEC's ROS is down by 28% YoY but it is up by 12% from the previous quarter

Dividends

What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALEC.

Financial health

How did Alector financials performed over time
ALEC's total assets is 87% greater than its total liabilities
The quick ratio has contracted by 44% YoY and by 24% from the previous quarter
Alector's current ratio has decreased by 43% YoY and by 24% from the previous quarter
The debt is 73% less than the equity
The debt to equity has soared by 108% year-on-year and by 23% since the previous quarter
The equity has decreased by 48% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.